Related Experiment Video
Updated: Aug 24, 2026
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus
Nadege Goutagny1, Claude Vieux, Evelyne Decullier
1Unité Mixte de Recherche 2142, Centre National de la Recherche Scientifique Biomérieux, Lyon, France.
Insights
Antiviral therapy for chronic Hepatitis C Virus (HCV) infection impairs plasmacytoid dendritic cell (PDC) function, reducing interferon-alpha (IFN-α) production. This suggests therapy, not HCV itself, affects PDC response.
Area of Science:
- Immunology
- Virology
- Hepatology
Background:
- Plasmacytoid dendritic cells (PDCs) are key producers of interferon-alpha (IFN-α) in peripheral blood mononuclear cells (PBMCs).
- Chronic Hepatitis C Virus (HCV) infection is a global health concern impacting the immune system.
Purpose of the Study:
- To investigate the functional status and number of PDCs in patients with chronic HCV infection.
- To determine the impact of antiviral therapy on PDC function and IFN-α production.
Main Methods:
- Analysis of IFN-α production capacity in PBMCs from five subject cohorts after viral stimulation.
- Concomitant assessment of PDC frequency and IFN-α transcript levels within PBMCs.
Main Results:
- PBMCs from HCV patients on antiviral therapy showed reduced IFN-α release compared to controls, long-term responders, and untreated patients.
- This reduced IFN-α production defect correlated with PDC percentage.
- PDCs from treated HCV patients exhibited an intrinsic reduction in IFN-α production capacity.
Conclusions:
- Antiviral therapy, rather than chronic HCV infection itself, appears to negatively affect PDC survival or localization.
- The findings highlight a therapy-induced immune modulation impacting antiviral responses.
Background:
Plasmacytoid dendritic cells (PDCs) are the major producers of interferon (IFN)- alpha within peripheral blood mononuclear cells (PBMCs).
Methods:
We analyzed whether chronic hepatitis C virus (HCV) infection could be linked to a defective function or number of PDCs. We evaluated the capacity of PBMCs from 5 cohorts of subjects to produce IFN- alpha after viral stimulation. We concomitantly analyzed the frequency of PDCs and the levels of IFN- alpha transcripts within the PBMCs from the same cohorts.
Results:
PBMCs from patients with chronic HCV infection receiving antiviral therapy displayed a reduced capacity to release IFN- alpha, compared with those from healthy individuals, those from long-term responders to therapy, and those from nontreated patients. This defect was significantly correlated with the percentage of PDCs. In addition, PDCs from patients with chronic HCV infection receiving therapy displayed a reduced intrinsic capacity to produce IFN- alpha, which could be linked to the level of IFN- alpha transcripts.
Conclusion:
Our observations point to an effect of the therapy on either the survival or the localization of PDCs, rather than a direct detrimental effect due to the viral infection during chronic HCV infection.
More Related Videos
08:11Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.
Published on: September 1, 2015
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
